Clinicopathological factors for predicting tumor response in hormonal positive/HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

被引：0
|
作者：
Yincharoen, P. [1 ]
Samarnthai, N. [2 ]
Korphaisarn, K. [3 ]
Imruetaicharoenchoke, W. [1 ]
机构：
[1] Mahidol Univ, Fac Med, Div Head Neck & Breast Surg, Dept Surg,Siriraj Hosp, Bangkok, Thailand
[2] Mahidol Univ, Fac Med, Dept Pathol, Siriraj Hosp, Bangkok, Thailand
[3] Mahidol Univ, Siriraj Hosp, Div Med Oncol, Dept Med,Fac Med, Bangkok, Thailand
来源：
BREAST | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P112
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [1] The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Saigosoom, Napat
    Sa-nguanraksa, Doonyapat
    O-charoenrat, Eng
    Thumrongtaradol, Thanawat
    O-charoenrat, Pornchai
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 2491 - 2499
  • [2] Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
    Matikas, A.
    Lovrot, J.
    Ramberg, A.
    Eriksson, M.
    Lindsten, T.
    Lekberg, T.
    Hedenfalk, I.
    Loman, N.
    Bergh, J.
    Erlandsson, A.
    Hatschek, T.
    Foukakis, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
    von Minckwitz, Gunter
    Eidtmann, Holger
    Rezai, Mahdi
    Fasching, Peter A.
    Tesch, Hans
    Eggemann, Holm
    Schrader, Iris
    Kittel, Kornelia
    Hanusch, Claus
    Kreienberg, Rolf
    Solbach, Christine
    Gerber, Bernd
    Jackisch, Christian
    Kunz, Georg
    Blohmer, Jens-Uwe
    Huober, Jens
    Hauschild, Maik
    Fehm, Tanja
    Mueller, Berit Maria
    Denkert, Carsten
    Loibl, Sibylle
    Nekljudova, Valentina
    Untch, Michael
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04): : 299 - 309
  • [4] Identification of lncRNAs via microarray analysis for predicting HER2-negative breast cancer response to neoadjuvant chemotherapy
    Ouyang, Dengjie
    Su, Juan
    Huang, Peng
    Li, Moyun
    Li, Qianying
    Zhao, Piao
    Chen, Qitong
    Zou, Qiongyan
    Feng, Xueping
    Qian, Ke
    Li, Lun
    Yi, Wenjun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (05): : 2621 - 2628
  • [5] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
    Bertucci, Francois
    Finetti, Pascal
    Viens, Patrice
    Birnbaum, Daniel
    CANCER LETTERS, 2014, 355 (01) : 70 - 75
  • [6] Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
    L S Rigter
    C E Loo
    S C Linn
    G S Sonke
    E van Werkhoven
    E H Lips
    H A Warnars
    P K Doll
    A Bruining
    I A Mandjes
    M J Vrancken Peeters
    J Wesseling
    K G Gilhuijs
    S Rodenhuis
    British Journal of Cancer, 2013, 109 : 2965 - 2972
  • [7] The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer.
    Brase, J. C.
    Gehrmann, M. C.
    Petry, C.
    Weber, K. E.
    Schmidt, M.
    Koelbl, H.
    Brauch, H.
    Schwab, M.
    Mueller, V.
    Jaenicke, F.
    Rody, A.
    Kaufmann, M.
    Filipits, M.
    Gnant, M.
    Denkert, C.
    Loibl, S.
    von Minckwitz, G.
    Kronenwett, R.
    CANCER RESEARCH, 2011, 71
  • [8] Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
    Rigter, L. S.
    Loo, C. E.
    Linn, S. C.
    Sonke, G. S.
    van Werkhoven, E.
    Lips, E. H.
    Warnars, H. A.
    Doll, P. K.
    Bruining, A.
    Mandjes, I. A.
    Peeters, M. J. Vrancken
    Wesseling, J.
    Gilhuijs, K. G.
    Rodenhuis, S.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 2965 - 2972
  • [9] Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
    In Hee Lee
    Soo Jung Lee
    Jeeyeon Lee
    Jin Hyang Jung
    Ho Yong Park
    Shin Young Jeong
    Sang-woo Lee
    Yee Soo Chae
    BMC Cancer, 20
  • [10] Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
    Lee, In Hee
    Lee, Soo Jung
    Lee, Jeeyeon
    Jung, Jin Hyang
    Park, Ho Yong
    Jeong, Shin Young
    Lee, Sang-woo
    Chae, Yee Soo
    BMC CANCER, 2020, 20 (01)
12345